April 4 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SIGNIFICANTLY REDUCE BOTH THE SIGNS AND SYMPTOMS AND THE PROGRESSION OF STRUCTURAL DAMAGE IN ADULTS LIVING WITH ACTIVE PSORIATIC ARTHRITIS
JOHNSON & JOHNSON - TREMFYA PHASE 3B STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
JOHNSON & JOHNSON - TREMFYA SAFETY PROFILE CONSISTENT WITH NO NEW SAFETY SIGNALS
JOHNSON & JOHNSON - TREMFYA SHOWS LESS STRUCTURAL DAMAGE PROGRESSION AT WEEK 24
Source text: ID:nPn70mvxba
Further company coverage: JNJ.N
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.